Bahadır ERTÜRK, Zamir Kemal ERTÜRK, Çiğdem ERTÜRK

AŞILAR VARYANT COVID-19 HASTALIĞINI ÖNLEMEDE ETKİN Mİ? BİR AŞILI VARYANT COVID-19 VAKASI

SARS-CoV-2 virüsünün neden olduğu COVID 19 hastalığı günümüzün en önemli halk sağlığı sorunudur. Bu virüsün oluşturduğu pandemi tüm dünyadaki yaşam biçimini köklü olarak değiştirdi. Bu virüse karşı geliştirilen aşılar ise elimizdeki en önemli savunma aracımız. Olgumuz iki doz aşılanmasına rağmen varyant COVID 19 hastalığına yakalan bir hastadır. Bu vaka üzerinden aşılanmanın önemi kadar kişisel ve sosyal önlemlere bir süre daha uymanın gereği vurgulanacaktır.

ARE VACCINES EFFECTIVE IN PREVENTING VARIANT COVID-19 DISEASE? A CASE OF VACCINATED VARIANT COVID-19

COVID 19 disease caused by the SARS-CoV-2 virus is the most important public health problem of today. The pandemic caused by this virus has radically changed the way of life all over the world. Vaccines developed against this virus are our most important defense tool. Our case is a patient with variant COVID 19 disease, despite two doses of vaccination. In this case, the importance of adhering to personal and social precautions for a while will be emphasized as well as the importance of vaccination.

PDF

___

1. Li H, Liu SM, Yu XH, Tang SL, Tang CK. Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents. 2020;55(5):105951. (doi:10.1016/j.ijantimicag.2020.105951).
2. Masters PS. The molecular biology of coronaviruses. Adv Virus Res. 2006;66:193-292. (doi:10.1016/s0065-3527(06)66005-3).
3. Wu Z, Hu Y, Xu M, ve ark. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;10.1016/s1473- 3099(20)30987-7. (doi:10.1016/s1473-3099(20)30987-7).
4. Zhang Y, Zeng G, Pan H, ve ark. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181-92. (doi:10.1016/s1473-3099(20)30843-4).
5. Weinreich DM, Sivapalasingam S, Norton T, ve ark. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med. 2021;384(3):238-51. (doi:10.1056/NEJMoa2035002).
6. Seyed Hosseini E, Riahi Kashani N, Nikzad H, Azadbakht J, Hassani Bafrani H, Haddad Kashani H. The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies. Virology. 2020;551:1-9. (doi:10.1016/j.virol.2020.08.011).
7. Malik YA. Properties of Coronavirus and SARS-CoV-2. Malays J Pathol. 2020;42(1):3-11.
8. Galloway SE, Paul P, MacCannell DR, ve ark. Emergence of SARS-CoV-2 B.1.1.7 Lineage - United States, December 29, 2020-January 12, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(3):95-9. (doi:10.15585/mmwr.mm7003e2).
9. Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet. 2020;395(10242):1973-87. (doi:10.1016/s0140- 6736(20)31142-9).
10. Muik A, Wallisch AK, Sänger B, ve ark. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. Science. 2021;371(6534):1152-3. (doi:10.1126/science.abg6105).